about
Targeting the tumor microenvironment to enhance antitumor immune responsesParticle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I InterferonThe ReNAissanCe of mRNA-based cancer therapy.Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells.Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome.Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.
P50
Q35176307-FD902EC3-3987-4907-AB0D-0B56C5505870Q37254639-5AAF8590-71D6-4622-8353-46F1773DA812Q38255012-EC5922D7-1672-4B9C-A495-A620F31E7B09Q38812261-879B3E45-75CC-4374-B4EA-71AAFE3C0AA8Q38836740-E5287547-7461-4E87-B256-6B000822933CQ41351026-F711E13A-9A52-4A22-904F-CE11E7954CF4Q54213159-BD6BE6A0-FA90-456C-A20F-CB0F20C85F90Q55348052-2EA96ACA-3B50-4D6E-AE39-F5EFC92ECF49Q64942268-59BE3627-E920-44B5-A40D-1EDA233194C8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Katrijn Broos
@ast
Katrijn Broos
@en
Katrijn Broos
@es
Katrijn Broos
@nl
type
label
Katrijn Broos
@ast
Katrijn Broos
@en
Katrijn Broos
@es
Katrijn Broos
@nl
prefLabel
Katrijn Broos
@ast
Katrijn Broos
@en
Katrijn Broos
@es
Katrijn Broos
@nl
P106
P31
P496
0000-0001-5512-0315